Table 4.

Summary of studies evaluating the effects of drugs targeting chemokines and their receptors in ICH.

Drug	Mechanism	Disease model	Drug administration details	Main effects	Signaling pathway	Reference
Propagermanium	CCR2 inhibitor	collagenase	Oral gavage: 3 times a day (25 mg/kg/day) for 1 day or 3 days	Reduce brain edema, improve neurobehavioral functions	CCL2-CCR2-p38 MAPK	Guo et al. (2020)
Maraviroc	CCR5 inhibitor	autologous blood	Intranasal delivery: once per day (50 μg/kg or 150 μg/kg or 450 μg/kg) for 3 days	Improve neurobehavioral deficits, decrease neuronal pyroptosis	CCR5/PKA/CREB	Yan et al. (2021)
Reparixin	CXCR1/2 antagonist	collagenase	Intravenous and intraperitoneal administrations: three times a day (15 mg/kg) for 3 days	Ameliorate neurological dysfunction	/	Matsushita et al. (2014)